Data Sheet (Cat.No.T6668)



SGC-CBP30

Chemical Properties


CAS No.: 1613695-14-9

Formula: C28H33ClN4O3

Molecular Weight: 509.04

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).	KO!	
Targets(IC50) Epigenetic Reader Domain, Histone Acetyltransferase			
In vivo	SGC-CBP30 exhibits moderate cytotoxicity in U2OS and HeLa cells.		

Solubility Information

Solubility

H2O: < 1 mg/mL (insoluble or slightly soluble),
Ethanol: 93 mg/mL (182.7 mM), Sonication is recommended.

DMSO: 93 mg/mL (182.7 mM), Sonication is recommended.

(< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9645 mL	9.8224 mL	19.6448 mL
5 mM	0.3929 mL	1.9645 mL	3.929 mL
10 mM	0.1964 mL	0.9822 mL	1.9645 mL
50 mM	0.0393 mL	0.1964 mL	0.3929 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

Reference

Structural Genomics Consortium

Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity. Cancer Immunology Research. 2022, 10(1): 87-107.

Wellinger L C, Hogg S J, Newman D M, et al. BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity[J]. bioRxiv. 2021

Wellinger L C, Hogg S J, Newman D M, et al. Bet inhibition enhances TNF-mediated antitumor immunity. Cancer Immunology Research. 2022, 10(1): 87-107

Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1[J]. Molecular biology of the cell. 2017 Dec 15;28(26):3756-3772.

Gendarme M, Baumann J, Ignashkova T I, et al. Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1. Molecular Biology of the Cell. 2017 Dec 15;28(26):3756-3772

Liu L, Deng P, Liu S, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death & Disease. 2023, 14(8): 513.

Pan X, Zhang W, Wang L, et al.KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. Molecular Oncology.2023

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com